494 related articles for article (PubMed ID: 18447656)
1. Comparison of scales for evaluating premenstrual symptoms in women using oral contraceptives.
Coffee AL; Kuehl TJ; Sulak PJ
Pharmacotherapy; 2008 May; 28(5):576-83. PubMed ID: 18447656
[TBL] [Abstract][Full Text] [Related]
2. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen.
Coffee AL; Kuehl TJ; Willis S; Sulak PJ
Am J Obstet Gynecol; 2006 Nov; 195(5):1311-9. PubMed ID: 16796986
[TBL] [Abstract][Full Text] [Related]
3. A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms.
Brown C; Ling F; Wan J
J Reprod Med; 2002 Jan; 47(1):14-22. PubMed ID: 11838304
[TBL] [Abstract][Full Text] [Related]
4. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval.
Sulak P; Willis S; Kuehl T; Coffee A; Clark J
Headache; 2007 Jan; 47(1):27-37. PubMed ID: 17355491
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.
Yonkers KA; Brown C; Pearlstein TB; Foegh M; Sampson-Landers C; Rapkin A
Obstet Gynecol; 2005 Sep; 106(3):492-501. PubMed ID: 16135578
[TBL] [Abstract][Full Text] [Related]
6. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms.
Sangthawan M; Taneepanichskul S
Contraception; 2005 Jan; 71(1):1-7. PubMed ID: 15639064
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Yasmin in premenstrual symptoms.
Taneepanichskul S; Jaisamrarn U; Phupong V
Arch Gynecol Obstet; 2007 Jun; 275(6):433-8. PubMed ID: 17111156
[TBL] [Abstract][Full Text] [Related]
9. Added benefits of drospirenone for compliance.
Foidart JM
Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
[TBL] [Abstract][Full Text] [Related]
10. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol.
Greco T; Graham CA; Bancroft J; Tanner A; Doll HA
Contraception; 2007 Jul; 76(1):8-17. PubMed ID: 17586130
[TBL] [Abstract][Full Text] [Related]
11. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen.
Coffee AL; Sulak PJ; Kuehl TJ
Contraception; 2007 Jun; 75(6):444-9. PubMed ID: 17519150
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism.
Batukan C; Muderris II
Fertil Steril; 2006 Feb; 85(2):436-40. PubMed ID: 16595223
[TBL] [Abstract][Full Text] [Related]
13. A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 microg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight.
Endrikat J; Sandri M; Gerlinger C; Rübig A; Schmidt W; Fortier M
Eur J Contracept Reprod Health Care; 2007 Sep; 12(3):220-8. PubMed ID: 17763260
[TBL] [Abstract][Full Text] [Related]
14. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive.
Graham CA; Sherwin BB
J Psychosom Res; 1992 Apr; 36(3):257-66. PubMed ID: 1564678
[TBL] [Abstract][Full Text] [Related]
15. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.
Borges LE; Andrade RP; Aldrighi JM; Guazelli C; Yazlle ME; Isaia CF; Petracco A; Peixoto FC; Camargos AF
Contraception; 2006 Dec; 74(6):446-50. PubMed ID: 17157100
[TBL] [Abstract][Full Text] [Related]
16. Patterns of mood changes throughout the reproductive cycle in healthy women without premenstrual dysphoric disorders.
Gonda X; Telek T; Juhász G; Lazary J; Vargha A; Bagdy G
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1782-8. PubMed ID: 18721843
[TBL] [Abstract][Full Text] [Related]
17. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life.
Borenstein J; Yu HT; Wade S; Chiou CF; Rapkin A
J Reprod Med; 2003 Feb; 48(2):79-85. PubMed ID: 12621790
[TBL] [Abstract][Full Text] [Related]
18. Oral contraceptives containing drospirenone for premenstrual syndrome.
Lopez LM; Kaptein AA; Helmerhorst FM
Cochrane Database Syst Rev; 2012 Feb; (2):CD006586. PubMed ID: 22336820
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.
Freeman EW
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():27-34; discussion 42-3. PubMed ID: 12659404
[TBL] [Abstract][Full Text] [Related]
20. Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen.
Marr J; Niknian M; Shulman LP; Lynen R
Contraception; 2011 Jul; 84(1):81-6. PubMed ID: 21664515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]